Antiangiogeneettinen hoito lapsipotilailla, joilla on pahanlaatuinen kasvain

EXTENDED ANGIOCOMB Antiangiogenetic therapy for pediatric malignancies with no conventional treatment modalities left

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2008-006989-28-FI

Enrollment

Registered

2008-11-05

Start date

2009-01-16

Completion date

Unknown

Last updated

2024-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric malignancies with no conventional treatment modalities left

Interventions

Trade Name: talidex Pharmaceutical Form: INN or Proposed INN: THALIDOMIDE CAS Number: 50351 Trade Name: celebra Pharmaceutical Form: INN or Proposed INN: CELECOXIB CAS Number: 169590425 Trade Name

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Pediatric malignancies with no conventional treatment modalities left Age 1-18 year Are the trial subjects under 18? yes Number of subjects for this age range: 20 F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Decline in consciousness, inability to swallow, need of opioids for pain

Design outcomes

Primary

Measure	Time frame
Main Objective: In the present research protocol we are proposing a phase II clinical trial for therapy of pediatric patients with malignancies without conventional treatment modalities left. Our aim is to explore whether the combination of thalidomide, celecoxib and etoposide would prolong survival and/or improve the quality of life in pediatric patients with malignancies without conventional treatment modalities left. The possible adverse effects of this combination therapy will be registered. ;Secondary Objective: Not applicable;Primary end point(s): - overall survival of pediatric patients with malignancies without conventional treatment modalities left - the quality of life in pediatric patients with malignancies without conventional treatment modalities left - the possible adverse effects of this combination therapy;Timepoint(s) of evaluation of this end point: every 3 months	—

Measure

Time frame

Main Objective: In the present research protocol we are proposing a phase II clinical trial for therapy of pediatric patients with malignancies without conventional treatment modalities left. Our aim is to explore whether the combination of thalidomide, celecoxib and etoposide would prolong survival and/or improve the quality of life in pediatric patients with malignancies without conventional treatment modalities left. The possible adverse effects of this combination therapy will be registered. ;Secondary Objective: Not applicable;Primary end point(s): - overall survival of pediatric patients with malignancies without conventional treatment modalities left - the quality of life in pediatric patients with malignancies without conventional treatment modalities left - the possible adverse effects of this combination therapy;Timepoint(s) of evaluation of this end point: every 3 months

—

Secondary

Measure	Time frame
Secondary end point(s): -;Timepoint(s) of evaluation of this end point: -	—

Countries

Finland

Contacts

Public ContactVirve Pentikäinen

HUCH, Hospital for Children and Adolescents

+358504272082

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026